Cure Today1h
Real-World Data May Support Opdivo Plus Yervoy Efficacy in mRCC
Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.
Renal & Urology News2d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Cure Today19h
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
The American Journal of Managed Care6d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Monthly Prescribing Reference7d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...
Targeted Oncology12d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Cancer Therapy Advisor9d
Opdivo Qvantig Approved to Treat Solid Tumor Malignancies
The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.
FiercePharma7d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Pharmabiz10d
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...